AC
ACHFF.US Arch Biopartners Inc
- Market cap
- USD 44.8M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is ACHFF.US undervalued?
Graham numberThe Graham number of Arch Biopartners Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arch Biopartners Inc fundamental analysis
No fundamental analysis for Arch Biopartners Inc yet.
Arch Biopartners Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, t…
Full company profileArch Biopartners Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arch Biopartners Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 93.9K | 67.9K | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -412K | -611K | -1.50M | -1.67M | - | - | - | - | - | - | - |
| Operating Income | -981K | -1.88M | -3.17M | -2.25M | -4.46M | -892K | -1.08M | -3.00M | -3.56M | -1.24M | -3.17M |
| EBITDA | - | -1.88M | -3.13M | -2.25M | -4.45M | -896K | -1.10M | -2.97M | -3.53M | -1.29M | -3.18M |
| Net Income | -1.01M | -1.90M | -3.20M | -2.36M | -4.63M | -1.17M | -1.39M | -3.33M | -3.92M | -1.55M | -3.41M |
| EPS | - | -0.03 | -0.05 | -0.04 | -0.08 | -0.02 | -0.02 | -0.05 | -0.06 | -0.02 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 227K | 67.9K | 673K | 568K | 741K | 2.67M | 622K | 1.17M | 936K | 105K | 57.2K |
| Total Liabilities | 484K | 631K | 1.72M | 3.47M | 4.61M | 6.55M | 5.09M | 6.68M | 5.28M | 3.99M | 4.04M |
| Shareholders' Equity | -257K | -563K | -1.05M | -2.90M | -3.87M | -3.88M | -4.47M | -5.51M | -4.35M | -3.88M | -3.99M |
| Cash & Short-term Investments | 200K | 42.6K | 544K | 400K | 654K | 448K | 506K | 831K | 2.97K | 2.10K | 2.91K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -731K | -760K | -2.15M | -1.80M | -1.90M | -2.98M | 479K | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -760K | -2.15M | -1.80M | -1.90M | -2.98M | 479K | -234K | -2.33M | -1.58M | -1.97M |
| Ratios | |||||||||||
| ROA | -443.4% | -2,803.2% | -475.4% | -415.1% | -624.4% | -43.8% | -223.5% | -284.1% | -419.0% | -1,485.5% | -5,955.2% |
| Net Profit Margin | - | - | - | -2,511.4% | -6,818.3% | -30.1% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Arch Biopartners Inc dividends
Arch Biopartners Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3 on Nov 26, 2003.
Who owns Arch Biopartners Inc
- Insiders 18.04%
- Institutions 0.00%
- Public & others 81.97%
- Shares outstanding 67.9M
- Free float 53.8M
Arch Biopartners Inc company profile
- Company name
- Arch Biopartners Inc
- Ticker
- ACHFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- 545 King Street West, Toronto, ON, Canada, M5V 1M1
- Phone
- 647-428-7031
- Website
- archbiopartners.com
About Arch Biopartners Inc
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.
Arch Biopartners Inc management
6- Mr. Richard Gabriel MuruveCo-Founder, CEO, President & Director · born 1971
- Dr. Daniel Abraham Muruve M.D.Co-Founder, Chief Science Officer & Member of Scientific Advisory Board
- Mr. Andrew Bishop CFACFO & Director · born 1966
- Dr. Justin MacDonald Ph.D.Co-Founder & Principal Scientist
- Dr. Paul BeckCo-Founder & Principal Scientist
- Mr. Aaron BensonDirector of Communications & Clinical Data Management